Fig. 5
From: Anti-Aβ antibodies bound to neuritic plaques enhance microglia activity and mitigate tau pathology
Effects of passive anti-Aβ immunization on Aβ pathology and microglia distribution. a Representative images of the Aβ staining (4G8, green) in the contralateral hippocampus of control sham-treated and mAb11-treated 5xFAD/AAV-tau mice. The white line delineates the hippocampal region of interest (ROI) used for analysis of Aβ pathology. DAPI staining is displayed in grey. Scale bars: 500 µm. b Number of Aβ positive plaques per mm2 detected in the hippocampal ROI. c Percentage of the hippocampal ROI covered by Aβ staining. d Average area of individual Aβ plaques. Note the significant increase in plaque size in mAb11-treated mice. e Representative images of 4G8-positive Aβ plaques in sham- and mAb11-treated mice. Note the lack of the diffuse fibrillary halo in the mAb11-treated condition. DAPI staining is shown in blue. Scale bars: 50 µm. f Representative images of Aβ deposits (6e10, in green) surrounded by microglia (Iba1, in white) in a sham-treated and a mAb11-treated 5xFAD/AAV-tau mouse. Shown in red, note the presence of microglia positive for the CD68 phagolysosome marker. DAPI is shown in blue. Scale bars: 25 µm. g, h Percentage of the plaque area (including a 5-µm wide rim as described in Fig. 4) covered by the Iba1 staining (g) and the CD68 staining (h), in the hippocampal region of either control sham-treated or mAb11-treated 5xFAD/AAV-tau mice. Note the significant effects of the mAb11 treatment on Aβ plaque coverage by Iba1- and CD68-positive microglial cells. Statistical analysis: unpaired two-tailed Student’s t-test, *p < 0.05, **p < 0.01, ****p < 0.0001; (b–d) Control sham-treated 5xFAD/AAV-tau: n = 14 mice, mAb11-treated 5xFAD/AAV-tau: n = 16 mice; (g, h) Control sham-treated 5xFAD/AAV-tau: n = 11 mice, mAb11-treated 5xFAD/AAV-tau: n = 15 mice